Vertex (VRTX) NDA for Vanza Triple Therapy Accepted by FDA
ZacksThe FDA accepts Vertex’s (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.
The FDA accepts Vertex’s (VRTX) new drug application for vanza triple therapy for people living with cystic fibrosis aged six years and above. A decision is due on Jan 2, 2025.